2BEEH K, BEIER J. Indacaterol, a novel inhaled, once- daily, long-acting beta2-agonist for the treatment of obstructive airways diseases [ J ]. Adv Ther, 2009, 26 (7) : 691-699.
3BARNES P J, POCOCK S J, MAGNUSSEN H, et al. In- tegrating indacaterol dose selection in a clinical study in COPD using an adaptive seamLess design [ J ]. Pulm Pharmacol Ther,2010,23 ( 3 ) : 165-171.
4DONOHUE J F, FOGARTY C, LOTVALL J, et al. Once- daily bronchodilators for chronic obstructive pulmonary disease:Indacaterolversus tiotropium[ J]. Am J Respir CritCare Med ,2010,182 (2) : 155-162.
5DAHL R, CHUNG K F, BUHL R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice daily formoterol in COPD [J]. Thorax ,2010,65 (6) :473-479.
6KORNMANN O, DAHL R, CENTANNI S, et al. Once- daily indaeaterol versus twice daily salmeterol for COPD:A placebo controlled comparison[ J ]. Eur Respir J, 2011,37 (2) :273-279.
7BEIER J, BEEH K M, BROOKMAN L, et al. Broncho- dilator effects of indacaterol and formoterol in patients with COPD [ J ]. Pulm Pharmacol Ther,2009,22 (6) :492-496.
8KORNMANN O,DAHL R, CENTANNI S,et al. Once-daily indacaterol versus twice daily salmeterol for COPD: A placebo controlled comparison [ J ]. Eur Respir J, 2011,37 (2) :273-279.
9BEIER J,BEEH K M, BROOKMAN L, et al. Bronchodilator effects of indaeaterol and formoterol in patients with COPD [ J ]. Pulm Pharmacol Ther,2009,22 (6) :492-496.
10VOGELMEIER C, RAMOS-BARBON D, ACK D, et al. Indacaterol provides 24-hour bronchodilation in COPD:A placebo controlled blinded comparison with tiotropium[J]. Respir Res ,2010,11 ( 1 ) : 135.
2GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
3Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
4Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
3Vestbo J, Hurd S S, Agusti A G, et al. Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease [ J ]. Am J Respir Crit Care Med,2013,187 (4) :347 -365.
4Ronald Dahl, Kian Fan Chung. Efcacy of a new once - daily long- acting inhaledb2 -agonist indaeaterol versus twice- daily formoterol in COPD[ J]. Thorax,2010,65:473 -479.
5Jones P W. St. George's Respiratory questionnaire: MCID [J]. COPD,2005(2):75 -79.
6Chung K F, Buhl R, Magnussen H, et al. Efficacy of a new once -daily long- acting inhaled beta2 -agonist indacaterol versus twice - daily formoterol in COPD [ J ]. Thorax, 2010, 65(6) :473 -479.
7Celli B R, Cote C G, Marin J M, et al. The body - mass in- dex, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease [ J ]. N Engl J Med, 2004,350 : 1005 - 1012.
8James F, Donohue, Jeroen P Jansen. Comparative efficacy of long - acting bronehodilators for COPD - a network meta - a- nalysis Shannon Copel, [ J ]. Respiratory Research ,2013,14 : 1 -18.
9Rennard S, Bantje T, Centanni S, et al. A dose -ranging study of indaeaterol in obstructive airways disease, with a tiotropium comparison [ J ]. Respir Med 2008,102 : 1033 - 1044.
10Bauwens O, Ninane V, Van de Maele B, et al. 24 -hour bronchodilator efficacy of single doses of indacaterol in sub- jects with COPD: comparison with placebo and ormoterol [ J]. Curr Med Res Opin,2009,25:463 -470.
